Permanent cardiac pacing in the Fontan circulation: therapeutic need or added risk factor?
Comprehensive review on the indications, approaches, and outcomes of permanent pacemaker implantation in patients with Fontan circulation.
Comprehensive review on the indications, approaches, and outcomes of permanent pacemaker implantation in patients with Fontan circulation.
This article summarizes the step-by-step TEVAR technique for complicated type B aortic dissection as described in the original study, and includes a final commentary where we integrate practical recommendations drawn from recent surgical articles, European guidelines, and the author’s own experience.
Consensus document from the Clinical Practice Standards Committee Working Group of the American Association for Thoracic Surgery on the management of pulmonary atresia with intact ventricular septum.
Report on the very long-term outcomes (15 years) of a single-surgeon experience at the Cleveland Clinic with aortic root reimplantation surgery.
Prospective observational study evaluating 5-year clinical outcomes of transcarotid TAVR in moderate-to-high surgical risk patients with no viable femoral access.
Second part of the consensus guidelines regarding the treatment and management of Ebstein´s anomaly in children and adults
Results from the US heart transplant program between 2016 and 2022, analyzing demographic characteristics, mortality, and 30-day readmissions in heart transplant recipients.
Editorial commentary on novel cannulation strategies in extracorporeal membrane oxygenation (ECMO) recently published in the Journal of Cardiothoracic and Vascular Anesthesia, proposing technical alternatives to standard VA or VV-ECMO support. These alternative approaches may be particularly valuable in cases of complex pathophysiology, high cardiac output, right ventricular failure, or when conventional devices are contraindicated.
This retrospective observational study evaluated 2250 patients who underwent TAVI, comparing outcomes based on the presence or absence of significant (moderate or greater) concomitant mitral regurgitation (MR).
Commentary on a reanalysis of the 4-year results from the Evolut Low Risk trial, excluding Abbott/St. Jude Trifecta prostheses from the surgical cohort.